Wenjia Feng

Ph.D. student at Washington University in Saint Louis interested in ctDNA liquid biopsy field.

Research Expertise

Bioinformatics
Cancer Research
Oncology
Radiology, Nuclear Medicine and imaging
Radiation
Computational Mathematics
Computational Theory and Mathematics
Computer Science Applications
Molecular Biology
Biochemistry
Statistics and Probability
Genetics

Legacy Map

Full View

Publications

Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study
PLOS Medicine
2021
Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study
PLOS Medicine
2021
Abstract 543: ctDNA MRD detection from plasma and urine and personalized oncogenomic analysis in oligometastatic colorectal cancer
Cancer Research
2021
Cell-Free DNA Alterations in the AR Enhancer and Locus Predict Resistance to AR-Directed Therapy in Patients With Metastatic Prostate Cancer
JCO Precision Oncology
2020
Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients
Unknown Venue
2022
Integrative analysis of urine cell-free DNA for the detection of residual disease in localized bladder cancer patients.
Journal of Clinical Oncology
2022
Correction: Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study
PLOS Medicine
2021
Tracking minimal residual disease with urine tumor DNA in muscle-invasive bladder cancer after neoadjuvant chemotherapy.
Journal of Clinical Oncology
2021
Urinary Tumor DNA Detection of Muscle-Invasive Bladder Cancer May be Superior to Surgical Pathologic Complete Response Status for Predicting Survival Outcomes
International Journal of Radiation Oncology*Biology*Physics
2020
Urinary cell-free DNA analysis for tumor mutation detection in patients with oligometastatic colorectal cancer.
Journal of Clinical Oncology
2020
PACT: a pipeline for analysis of circulating tumor DNA
Bioinformatics
2023
Abstract 6698: Combinatorial genomic and epigenomic cell-free DNA analysis of high-risk metastatic castration resistant prostate cancer reveals prognostic liquid biopsy signatures
Cancer Research
2023
Abstract 2219: Urine cell-free DNA multi-omics to detect molecular residual disease and predict survival in bladder cancer patients
Cancer Research
2023
86. Whole genome sequencing of mouse derived cell-free DNA to develop a NF1-MPNST-PDX liquid biopsy model
Cancer Genetics
2022
28. Detection of small mutations, copy number alterations and structural variations from targeted cfDNA sequencing in cancer
Cancer Genetics
2022
65. AR/enhancer alterations in metastatic castrate-resistant prostate cancer patient plasma predicts worse overall survival
Cancer Genetics
2022
Multimodal Urine Cell-Free DNA-Based Residual Disease Detection and Prognostication in Muscle-Invasive Bladder Cancer Patients
International Journal of Radiation Oncology*Biology*Physics
2022
Abstract B006: Development of a NF1-MPNST-PDX liquid biopsy model using whole-genome sequencing and quantitative PCR of mouse-derived cell-free DNA
Clinical Cancer Research
2022
Liquid biopsy AR/enhancer alteration detection before AR-targeted therapy and correlation with survival in metastatic castrate-resistant prostate cancer patients.
Journal of Clinical Oncology
2022
Urine- and Plasma-Based Detection of Minimal Residual Disease in Localized Bladder Cancer Patients
International Journal of Radiation Oncology*Biology*Physics
2021
Abstract 550: Cell-free DNA alterations in the AR/enhancer locus measured before AR signaling inhibition portend poor overall survival in metastatic castration resistant prostate cancer patients
Cancer Research
2021
Abstract 577: A unified pipeline to detect small mutations, structural variations and copy number alterations from targeted cell-free DNA sequencing in cancer
Cancer Research
2021
Abstract 547: Urine tumor DNA MRD detection and correlation with pathologic complete response in muscle-invasive bladder cancer treated with curative-intent radical cystectomy
Cancer Research
2021
00005 Urine tumor DNA detects minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy
Journal of Clinical and Translational Science
2021
Size-based Enrichment Of Urinary Cell-free DNA Compared To Plasma Cell-free DNA For Liquid Biopsy Analysis Of Oligometastatic Colorectal Cancer
International Journal of Radiation Oncology*Biology*Physics
2020
Can Ultra-low-pass Whole Genome Sequencing from Blood Plasma Detect Transformation to Malignant Peripheral Nerve Sheath Tumor in Patients with Neurofibromatosis Type I?
International Journal of Radiation Oncology*Biology*Physics
2020
Abstract LB-269: Detection of cell-free DNA alterations in AR and its enhancer significantly outperformed CTC AR-V7 detection for identifying treatment resistance in patients with metastatic prostate cancer
Cancer Research
2020
AR enhancer and locus genomic alterations as cell-free DNA biomarkers of primary resistance to AR-directed treatment of metastatic prostate cancer.
Journal of Clinical Oncology
2020
Practical Evaluation of Different Omics Data Integration Methods
Precision Health and Medicine
2019
Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: a cross-sectional study
Unknown Venue
2021
Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients
npj Precision Oncology
2023
ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine
JCO Precision Oncology
2021

Education

Saint Louis University

Master of Science, Bioinformatics & Computational Biology / May, 2018

Saint Louis, Missouri, United States of America

Washington University in St. Louis

Ph.D., Computational and System Biology / May, 2028 (anticipated)

St Louis, Missouri, United States of America

Experience

Washington University in Saint Louis

Bioinformatician / July, 2018July, 2023

Join Wenjia on NotedSource!
Join Now

At NotedSource, we believe that professors, post-docs, scientists and other researchers have deep, untapped knowledge and expertise that can be leveraged to drive innovation within companies. NotedSource is committed to bridging the gap between academia and industry by providing a platform for collaboration with industry and networking with other researchers.

For industry, NotedSource identifies the right academic experts in 24 hours to help organizations build and grow. With a platform of thousands of knowledgeable PhDs, scientists, and industry experts, NotedSource makes connecting and collaborating easy.

For academic researchers such as professors, post-docs, and Ph.D.s, NotedSource provides tools to discover and connect to your colleagues with messaging and news feeds, in addition to the opportunity to be paid for your collaboration with vetted partners.

Expert Institutions
NotedSource has experts from Stanford University
Expert institutions using NotedSource include Oxfort University
Experts from McGill have used NotedSource to share their expertise
University of Chicago experts have used NotedSource
MIT researchers have used NotedSource
Proudly trusted by
Microsoft uses NotedSource for academic partnerships
Johnson & Johnson academic research projects on NotedSource
ProQuest (Clarivate) uses NotedSource as their industry academia platform
Slamom consulting engages academics for research collaboration on NotedSource
Omnicom and OMG find academics on notedsource
Unilever research project have used NotedSource to engage academic experts

Connect with researchers and scientists like Wenjia Feng on NotedSource to help your company with innovation, research, R&D, L&D, and more.